Minireviews
Copyright ©The Author(s) 2024.
World J Gastrointest Pharmacol Ther. Nov 5, 2024; 15(6): 97381
Published online Nov 5, 2024. doi: 10.4292/wjgpt.v15.i6.97381
Table 1 Pharmacological agents for non-alcoholic steatohepatitis
Drug
Mechanism of action
Side effects
Stage of clinical trials
Vitamin EAntioxidant, reduces oxidative stress, modulates NF-kB pathwayNausea, diarrhea, increased bleeding risk, prostate cancer concernsApproved for use in NAFLD/NASH, widely recommended
GLP-1 RAs (e.g., Semaglutide, Liraglutide)Increases insulin secretion, suppresses glucagon, reduces steatosis and inflammationNausea, diarrhea, risk of pancreatitisPhase II and III trials ongoing
PioglitazoneActivates PPAR-γ, improves insulin sensitivity, reduces liver fatWeight gain, fluid retention, bone loss, risk of heart failurePhase II and III trials completed
Obeticholic Acid FXR agonist, reduces hepatic inflammation and fibrosis, promotes bile secretionPruritus, dyslipidemia (increased LDL, decreased HDL), fatiguePhase III trials (REGENERATE study)
LanifibranorPan-PPAR agonist, modulates lipid metabolism, reduces inflammationFatigue, nausea, diarrheaPhase III trials ongoing
SaroglitazarDual PPAR-α/γ agonist, reduces liver fat, improves insulin resistanceGastrointestinal symptoms, rashPhase II trials ongoing
Cenicriviroc CCR2/CCR5 antagonist, reduces liver inflammation and fibrosisFatigue, diarrhea, headachesPhase III trials (AURORA study)
SelonsertibASK1 inhibitor, reduces fibrosis and inflammationNausea, diarrhea, fatigueFailed in Phase III trials
Table 2 Diagnostic techniques for liver fibrosis in nonalcoholic fatty liver disease/non-alcoholic steatohepatitis
Diagnostic technique
Method
Advantages
Limitations
Liver biopsy
Invasive procedure, histological assessmentGold standard, provides detailed fibrosis stagingInvasive, sampling variability, associated risks
Vibration-controlled transient elastographyUltrasound-based, measures liver stiffnessNon-invasive, widely usedLess accurate in obese patients, influenced by inflammation
MREMRI-based imaging, measures tissue stiffnessMore accurate than Fibroscan for fibrosis and steatosisHigh cost, limited availability
APRIBlood-based, calculates fibrosis riskNon-invasive, low costLower sensitivity in early fibrosis
ELF testBlood-based, measures biomarkers of fibrosisHigh sensitivity and specificity for advanced fibrosisCostly, limited access in some regions